Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Prescription Generic Deal
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Prescription Generic Deal
雷迪博士尋求通過梅恩製藥公司的美國處方通用交易在女性健康方面立足
- Dr. Reddy's Laboratories Ltd (NYSE:RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC:MAYND) (OTC:MAYNF) (OTC:MYPHY).
- Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of approximately $90 million in cash, with contingent payments of up to $15 million.
- Consideration towards inventory and credits for certain accrued channel liabilities are to be determined on the closing date.
- The portfolio includes approximately 45 commercial, four pipeline, and 40 approved non-marketed products, including several generic products focused on women's health.
- For FY ended June 30, 2022, Mayne Pharma reported total revenue of $111 million for the acquired portfolio.
- Approved products include a hormonal vaginal ring, a birth control pill, and a cardiovascular product.
- The acquisition will complement Dr. Reddy's U.S. retail prescription pharmaceutical business with limited competition products.
- Marc Kikuchi, CEO, North America business, Dr. Reddy's, said, "This important acquisition provides our North America organization with a significant foothold in the women's health space."
- Erez Israeli, CEO, Dr. Reddy's, said, "The U.S. has always been an important market for us. The portfolio of products acquired from Mayne Pharma is a strategic fit with our growth objectives. The portfolio includes some high entry-barrier products. It also complements our existing portfolio by introducing products focused on women's health."
- Price Action: RDY shares traded lower by 0.29% at $54.01 on the last check Monday.
- 雷迪博士實驗室有限公司 (NYSE: RDY) 已同意收購位於澳大利亞的美國通用處方產品組合 美陽醫藥集團有限公司 （OTC：可能）（OTC：梅恩夫）（OTC：麥氏）。
- 根據協議條款，Reddy 博士將以約 9000 萬美元的現金預付款收購該投資組合，或有付款高達 1500 萬美元。
- 某些應計渠道負債的庫存和抵免額的考慮將在截止日期確定。
- 該產品組合包括約 45 種商業產品，四條產品線和 40 種經批准的非銷售產品，包括幾種專注於女性健康的通用產品。
- 對於截至 2022 年 6 月 30 日的財政年度，梅恩製藥公司報告該收購投資組合的總收入為 1.11 億美元。
- 批准的產品包括荷爾蒙陰道環，避孕藥和心血管產品。
- 此次收購將以有限的競爭產品與 Reddy 博士的美國零售處方藥業務相輔相成。
- 北美業務執行長 Marc Kikuchi 博士 Reddy's 博士表示：「這項重要的收購為我們的北美組織在婦女健康領域奠定了重要的立足點。」
- 雷迪博士首席執行官埃雷斯以色列說：「美國一直是我們的重要市場。從 Mayne Pharma 收購的產品組合與我們的成長目標完美契合。該產品組合包括一些高入門障礙產品。它還通過推出專注於女性健康的產品來補充我們現有的產品組合。」
- 價格行動： RDY 股票在周一上次檢查時下跌 0.29%，報 54.01 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。